- Home
- SHOT vs ATRA Comparison
SHOT vs ATRA Comparison
Compare SHOT & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- ATRA
- Stock Information
- Founded
- SHOT 2018
- ATRA 2012
- Country
- SHOT United States
- ATRA United States
- Employees
- SHOT N/A
- ATRA N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHOT Health Care
- ATRA Health Care
- Exchange
- SHOT Nasdaq
- ATRA Nasdaq
- Market Cap
- SHOT 33.4M
- ATRA 32.4M
- IPO Year
- SHOT 2020
- ATRA 2014
- Fundamental
- Price
- SHOT $0.45
- ATRA $6.17
- Analyst Decision
- SHOT
- ATRA Buy
- Analyst Count
- SHOT 0
- ATRA 5
- Target Price
- SHOT N/A
- ATRA $17.75
- AVG Volume (30 Days)
- SHOT 737.5K
- ATRA 47.4K
- Earning Date
- SHOT 05-14-2025
- ATRA 05-08-2025
- Dividend Yield
- SHOT N/A
- ATRA N/A
- EPS Growth
- SHOT N/A
- ATRA N/A
- EPS
- SHOT N/A
- ATRA N/A
- Revenue
- SHOT $701,967.00
- ATRA $128,940,000.00
- Revenue This Year
- SHOT N/A
- ATRA N/A
- Revenue Next Year
- SHOT N/A
- ATRA N/A
- P/E Ratio
- SHOT N/A
- ATRA N/A
- Revenue Growth
- SHOT 246.36
- ATRA 1404.02
- 52 Week Low
- SHOT $0.34
- ATRA $5.01
- 52 Week High
- SHOT $2.14
- ATRA $19.00
- Technical
- Relative Strength Index (RSI)
- SHOT 49.11
- ATRA 47.91
- Support Level
- SHOT $0.36
- ATRA $5.16
- Resistance Level
- SHOT $0.53
- ATRA $6.11
- Average True Range (ATR)
- SHOT 0.05
- ATRA 0.61
- MACD
- SHOT 0.01
- ATRA 0.08
- Stochastic Oscillator
- SHOT 57.59
- ATRA 78.98
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).